Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing

Murakami, Shuji; Yokose, Tomoyuki; Nemoto, Daiji; Suzuki, Masaki; Usui, Ryou; Nakahara, Yoshiro; Kondo, Tetsuro; Kato, Terufumi; Saito, Haruhiro

doi:10.20944/preprints202101.0448.v1

Cited by 6 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 It is also important to consider trying another sampling method, such as EBUS-TBNA, CTNB and surgical biopsy, if the specimen obtained from EBB/TBB is not appropriate for NGS analysis. 7,8,10 There were several limitations to this study. First, this study was a small retrospective study, therefore, further evaluation with a larger cohort is required.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, a novel 1.1 mm cryoprobe, which can pass through the 1.7 mm working channel of a BF‐MP 290F, became available in clinical settings, and therefore it is expected that large specimens can even be collected with an ultrathin bronchoscope 17 . It is also important to consider trying another sampling method, such as EBUS‐TBNA, CTNB and surgical biopsy, if the specimen obtained from EBB/TBB is not appropriate for NGS analysis 7,8,10 …”

Section: Discussionmentioning

confidence: 99%

“…The results for the ODxTT for each group are shown in Table 2. The median number of samples collected were comparable in the three groups; Group A: nine times (range [2][3][4][5][6][7][8][9][10][11][12]), group B: 10 times (range [6][7][8][9][10][11][12][13][14][15]), group C: 8.5 times (range [3][4][5][6][7][8][9][10][11][12]). The success rate of the ODxTT in group C (70%) was lower than that in the combined groups A and B (83% [group A: 85%, group B: 82%]) (p = 0.20).…”

Section: Success Rate Of the Odxttmentioning

confidence: 99%

“…Although the quantity of tumor cells in these biopsy samples is smaller than in surgical samples, some reports have shown the good feasibility of NGS panel testing using small biopsy samples. [6][7][8] Standard forceps biopsy is generally recommended to obtain enough sample material for NGS analysis compared with small forceps biopsy for EBB/TBB; however, the comparison of analytical performance for NGS based on the different size of biopsy forceps on EBB/TBB remains little known.…”

Section: Introductionmentioning

confidence: 99%

“…For patients with advanced lung cancer, the pathological diagnosis and biomarker tests have mostly been obtained with small biopsy samples, such as endobronchial biopsy/transbronchial biopsy (EBB/TBB), endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) and CT‐guided needle biopsy (CTNB). Although the quantity of tumor cells in these biopsy samples is smaller than in surgical samples, some reports have shown the good feasibility of NGS panel testing using small biopsy samples 6–8 . Standard forceps biopsy is generally recommended to obtain enough sample material for NGS analysis compared with small forceps biopsy for EBB/TBB; however, the comparison of analytical performance for NGS based on the different size of biopsy forceps on EBB/TBB remains little known.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non‐small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Background Next‐generation sequencing (NGS) has been implemented in clinical oncology to analyze multiple genes and to guide targeted therapy. Although the pathological diagnosis and biomarker tests for patients with advanced lung cancer have mostly been obtained with small biopsy samples, especially with bronchoscopic approaches, the performance for NGS with respect to the different sizes of biopsy forceps remains little known. Methods We retrospectively reviewed consecutive patients with non‐small cell lung cancer, whose FFPE samples were obtained by endobronchial biopsy/transbronchial biopsy and were submitted for the Oncomine Dx Target Test (ODxTT). We compared the analytical performance for ODxTT with respect to the size of biopsy forceps. Results A total of 103 samples were identified. The success rate of the ODxTT for the group with all samples obtained with small forceps biopsies (70%) was lower than that of the group with some or all samples obtained with standard forceps biopsies (83%), although without a statistically significant difference (p = 0.20). With regard to the reason for unsuccessful analysis, the proportion of the samples which did not pass the nucleic acid concentration threshold in the former group (15%) was higher compared with that of the latter group (4%) (p = 0.08). The proportion of tissue size 4 mm2 or larger in the former group (70%) was lower than that in the latter group (93%) (p = 0.01). Conclusion The analysis of ODxTT for specimens biopsied using only small forceps is prone to be unsuccessful due to an insufficient amount of nucleic acid.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Success Rate Of the Odxttmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non‐small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: As the number of genetic mutations that must be tested increases, the Oncomine Dx Target test (ODxTT), which can simultaneously detect multiple cancerrelated genes is becoming the main test used in preference to single-molecule testing. In this study, we evaluated the performance of ODxTT and cobas EGFR mutation test v2 (cobas EGFR), one of the single-molecule tests, in detecting EGFR mutations. Methods: Samples from 211 patients diagnosed with NS-NSCLC were tested simultaneously or sequentially with the cobas EGFR mutation test and ODxTT. We compared the success and detection rates of both tests and evaluated their equivalence by determining the concordance rate and k-coefficient of both tests. Results: The success rate in detecting EGFR mutations was 95.7% for ODxTT and 100% for cobas EGFR. EGFR mutations were detected in 26.5% of samples with ODxTT and in 28.0% with cobas EGFR. For the 200 samples successfully analyzed with both tests, the concordance rate and k-coefficient were 97.5% and 0.938, respectively. ODxTT failed to detect two exon 19 deletion mutations (p.E746_P753delinsVS and p.E746_P753delinsLS), and cobas EGFR failed to detect three instances of an exon 19 deletion (p.L747_P753delinsS), L861R, and an exon 20 insertion. Discussion: The success rate of ODxTT is slightly inferior to that of cobas EGFR. ODxTT shared a high concordance rate and k-coefficient with cobas EGFR in detecting EGFR mutations, but discordant results between the two tests were observed in a few cases, mainly due to the difference of detectable EGFR variants.

show abstract

Value of adding ultrathin bronchoscopy to thin bronchoscopy for peripheral pulmonary lesions: A multicentre prospective study

et al. 2022

View full text Add to dashboard Cite

Background and Objective The diagnostic yield of thin bronchoscopy with radial probe endobronchial ultrasound (rEBUS) of peripheral pulmonary lesions into which the rEBUS probe cannot be inserted is unsatisfactory. In such cases, adding ultrathin bronchoscopy may be an option. We evaluated the efficacy of sequential ultrathin bronchoscopy for peripheral pulmonary lesions into which the rEBUS probe could not be inserted during thin bronchoscopy. Methods In this multicentre prospective study, patients with peripheral pulmonary lesions ≤30 mm in diameter underwent rEBUS‐guided transbronchial biopsy using a 4.0 mm diameter thin bronchoscope. In patients with lesions into which a rEBUS probe could not be inserted using that bronchoscope, bronchoscopy using a 3.0 mm diameter ultrathin bronchoscope was performed. Results A total of 342 patients were enrolled and 340 were analysed. Among them, 87 patients with lesions of a median longest diameter of 17.5 mm underwent thin bronchoscopy followed by ultrathin bronchoscopy. Of the 87 patients, the rEBUS probe was successfully inserted into the lesions via the ultrathin bronchoscope in 50 patients (57.5%). Of the 87 patients, the diagnostic yields of thin bronchoscopy and ultrathin bronchoscopy were 12.6% (11 of 87) and 41.4% (36 of 87), respectively (p < 0.001). Conclusion Ultrathin bronchoscopy affords a higher diagnostic yield for lesions into which a rEBUS probe cannot be inserted via a thin bronchoscope.

show abstract

Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing

Cited by 6 publications

References 15 publications

Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non‐small cell lung cancer

Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non‐small cell lung cancer

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations

Value of adding ultrathin bronchoscopy to thin bronchoscopy for peripheral pulmonary lesions: A multicentre prospective study

Contact Info

Product

Resources

About